Meeting
2016 ASCO Annual Meeting
Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort.
Authors
Yan Ning
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Yan Ning , Sebastian Stintzing , Wu Zhang , Dongyun Yang , Diana L. Hanna , Satoshi Okazaki , Martin D. Berger , Yuji Miyamoto , Jordan David West , Mitsukuni Suenaga , Marta Schirripa , Afsaneh Barzi , Volker Heinemann , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3586)
DOI
10.1200/JCO.2016.34.15_suppl.3586
Abstract #
3586
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2015 ASCO Annual Meeting
Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.
First Author: Anish Parekh
Poster
2014 ASCO Annual Meeting
High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797).
First Author: Wu Zhang
Poster
2017 Gastrointestinal Cancers Symposium
Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger